Entia Biosciences, Inc.
ERGO
$0.0001
-$0.0001-50.00%
| 12/31/2016 | 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | |
|---|---|---|---|---|---|
| Revenue | 46.00K | 41.90K | 98.40K | 79.20K | 68.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.00K | 41.90K | 98.40K | 79.20K | 68.40K |
| Cost of Revenue | 10.10K | 13.40K | 35.60K | 32.40K | 31.10K |
| Gross Profit | 35.90K | 28.40K | 62.80K | 46.80K | 37.30K |
| SG&A Expenses | 371.60K | 299.80K | 353.20K | 316.80K | 208.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 381.70K | 313.20K | 388.80K | 349.10K | 239.40K |
| Operating Income | -335.70K | -271.40K | -290.30K | -269.90K | -171.00K |
| Income Before Tax | -432.80K | -288.80K | -401.60K | -272.60K | -303.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -432.80K | -288.80K | -401.60K | -272.60K | -303.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -432.80K | -288.80K | -401.60K | -272.60K | -303.30K |
| EBIT | -335.70K | -271.40K | -290.30K | -269.90K | -171.00K |
| EBITDA | -332.20K | -266.60K | -285.60K | -265.20K | -164.00K |
| EPS Basic | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 28.15M | 28.14M | 28.14M | 28.12M | 29.11M |
| Average Diluted Shares Outstanding | 28.15M | 28.14M | 28.14M | 28.12M | 29.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
